Lotus Eye Hospital and Institute growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+8.4%+4.5%
EBITDA−1.5%−23.6%
Net Income−89.1%−73.0%
EPS (adj.)−89.1%−73.0%
Total Assets+18.7%+9.3%
Total Equity+0.2%+1.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

LOTUSEYE₹110.00

Lotus Eye Hospital and Institute Limited

· Pharma & Health
₹ CrorePeersGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹229 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+8.4+4.5
EBITDA-1.5-23.6
Net Income-89.1-73.0
EPS (adj.)-89.1-73.0
Total Assets+18.7+9.3
Total Equity+0.2+1.5
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.